Kraków. Sobota, 21 października 2017 roku. Imieniny: Celiny, Hilarego, Janusza
    Strona główna
      Aktualności
      Hematologia
      Interna
      Proktologia
      Publikacje
      Prezentacje
      HEMORON
      Lekarz
      Zakres porad
      Uprawnienia
      Kontakt
      Adresy, linki
      Fotogaleria
"Pamiętaj o tym, że twoje swobodne i wolne od zajęć chwile obciążone są największymi zadaniami i odpowiedzialnością." - św. Augustyn
  dr hab. n. med. Artur Jurczyszyn

  Specjalista chorób wewnętrznych, hematolog
CZYTELNIA

Publikacje

New drugs in multiple myeloma - role of carfilzomibe and pomalidomide. Praca poglądowa

Jurczyszyn Artur, Legieć Wojciech, Helbig Grzegorz, Hus Marek, Kyrcz-Krzemień Sławomira, Skotnicki B. Aleksander



Współczesna Onkologia

Streszczenie:
Carfilzomib (CFZ) - an epoxyketone with specific chymotrypsine -like activity is a second-generation proteasome inhibitor with a significant activity in patients with relapsed and refractory multiple myeloma (MM). On July 20, 2012, the US Food and Drug Administration approved CFZ to treat patients with multiple myeloma who have received at least two prior therapies including bortezomib (BORT) and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalidomide (POM) is a novel immunomodulatory derivative (IMID) with stronger in vitro antimyeloma effect if compared with "older" IMIDs - thalidomide and lenalidomide (LEN). On February 8, 2013, the US Food and Drug Administration approved POM for the treatment of MM patients who have received at least two prior therapies including LEN and BORT and have demonstrated progression on or within 60 days of completion of the last therapy.

Słowa kluczowe: multiple myeloma, treatment, carflizomibe, pomalidomide

Abstract:
Carfilzomib (CFZ) an epoxyketone with specific chymotrypsine-like activity is a second-generation proteasome inhibitor with significant activity in patients with relapsed and refractory multiple myeloma. On July 20, 2012, the US Food and Drug Administration approved CFZ to treat patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Cytogenetic abnormalities did not appear to have an significant impact on the CFZ activity. CFZ was well tolerated and demonstrated promising efficacy in patient with renal insufficiency. Pomalidomide (CC-4047) is a novel immunomodulatory derivative (IMID) with stronger in vitro anti-myeloma effect if compared with “older” IMIDs - thalidomide and lenalidomide. On February 8, 2013, the US Food and Drug Administration approved POM (Pomalyst, Celgene) for the treatment of MM patients who have received at least two prior therapies including LEN and BORT and have demonstrated progression on or within 60 days of completion of the last therapy. POM is a novel IMIDs with a significant anti-myeloma activity and manageable toxicity. This compound has shown the high efficacy in MM patients who were resistant to prior use of LEN/BORT as well as in the patients with high-risk cytogenetic profile. CFZ and POM has very high efficacy and it will be use also in first line therapy in future.

Pełna wersja publikacji [plik PDF]

Publikacje
Wszystkie artykuły w tym dziale:

Do góry  

Specjalista chorób wewnętrznych, specjalista hematolog
CZYTELNIA: Hematologia | Interna | Proktologia | Publikacje | Prezentacje | HEMORON ©
PORADY I BADANIA: Lekarz | Zakres porad | Uprawnienia | KONTAKT
POZOSTAŁE INFORMACJE: Aktualności | Adresy, linki | Fotogaleria | Home

Copyright © dr hab. n. med. Artur Jurczyszyn, specjalista chorób wewnętrznych, specjalista hematolog
Prywatna Praktyka Internistyczna, Kraków, tel. kom.: +48 601 539 077



Projekt, wykonanie: piotrK 2005 & ZdroweMiasto.PL  
Opieka techniczna & administracja: PERITUS
zdrowemiasto.pl & zdrowapolska.pl

Centrale telefoniczne